Decrease in antibiotic use, an added benefit of PCVs

The Lancet Infectious Diseases

Volumn 14, Issue 3, 2014, Pages 175-177

  Grijalva, Carlos G ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CARRIER PROTEINS; FEMALE; HUMANS; IMMUNOGLOBULIN D; LIPOPROTEINS; MALE; OTITIS MEDIA; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES;

ANTIBIOTIC AGENT; HAEMOPHILUS INFLUENZAE VACCINE; MACROLIDE; PNEUMOCOCCUS VACCINE;

ACUTE OTITIS MEDIA; ANTIBIOTIC RESISTANCE; CHILD; COST EFFECTIVENESS ANALYSIS; DRUG USE; FINLAND; HEALTH EDUCATION; HUMAN; INFECTION PREVENTION; NOTE; OTITIS MEDIA; OUTPATIENT; PNEUMOCOCCAL INFECTION; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); VACCINATION;

EID: 84894320516     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70356-6     Document Type: Note

References (16)

1. Schrag SJ, Beall B, Dowell SF Limiting the spread of resistant pneumococci: biological and epidemiologic evidence for the effectiveness of alternative interventions. Clin Microbiol Rev 2000, 13:588-601.
2. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201:32-41.
3. Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG U.S. Hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 2013, 369:155-163.
4. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007, 369:1179-1186.
5. Dagan R, Klugman KP Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis 2008, 8:785-795.
6. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003, 349:1341-1348.
7. Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006, 354:1455-1463.
8. Hampton LM, Farley MM, Schaffner W, et al. Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines. J Infect Dis 2012, 205:401-411.
9. Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J 2003, 22:10-16.
10. Dagan R, Sikuler-Cohen M, Zamir O, Janco J, Givon-Lavi N, Fraser D Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees. Pediatr Infect Dis J 2001, 20:951-958.
11. Wilby KJ, Werry D A review of the effect of immunization programs on antimicrobial utilization. Vaccine 2012, 30:6509-6514.
12. Beutels P, Thiry N, Van Damme P Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination-a review (2002-2006). Vaccine 2007, 25:1355-1367.
13. Palmu AA, Jokinen J, Nieminen H, et al. Effect of pneumococcal Haemophilus Influenzae protein D conjugate vaccine (PHiD-C) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3-4 trial. Lancet Infect Dis 2013, published online Nov 26. http://dx.doi.org/10.1016/S1473-3099(13)70338-4.
14. Palmu AA, Jokinen J, Borys D, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 2013, 381:214-222.
15. Lauer MS, D'Agostino RB The randomized registry trial-the next disruptive technology in clinical research?. N Engl J Med 2013, 369:1579-1581.
16. Stoecker C, Hampton LM, Link-Gelles R, Messonnier ML, Zhou F, Moore MR Cost-effectiveness of using 2 vs 3 primary doses of 13-valent pneumococcal conjugate vaccine. Pediatrics 2013, 132:e324-e332.